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Ptk2, Cyp11b1, Shoc2, and Dusp5 (for further discussion,
see Results and Discussion sections in the Online
Repository). Together with the previously identified candidates
Gilz and Bach2, many of these genes were identified as members
of the mitogen-activated protein kinase/extracellular
signal-regulated kinase (MAPK/ERK) signaling pathway
(Fig 2, E).
Finally, we performed further genome-wide scans for linkage
at each day after immune challenge up to D4, also comparing the
linkage peaks detected here with those associated with
nonrecovery at D7. This allowed the confirmation of previously
identified loci that failed to reach statistical significance
across multiple time points and identification of additional
candidate genes (for further discussion, see Fig E2 and
Results and Discussion sections in this article’s Online
Repository at www.jacionline.org).
In this study, we have demonstrated that genetic variability
underlies substantial differences in CHS responses and we have
identified genetic loci strongly associated with the response to
CHS immune challenge in the mouse. The most important
associations were with the level of inflammation (acute response
to immune challenge), and level of recovery (postchallenge
recovery), which both revealed strong gene candidates explaining
the observed phenotype. These were identified as Bach2 andGilz,
respectively, and are of significant interest because both are
known modifiers of CHS and immune responses in general.7,8
Beyond these 2 genes, we have also identified a large number
of additional loci and candidate genes possibly associated with
the CHS response in multiple independent analyses over time.
Altogether, these findings point to the possibility that the
MAPK/ERK signaling pathway is a key regulator of the
development and recovery of CHS.
In conclusion, our data overwhelmingly support a strong
genetic basis for the development of ACD. The intensity of the
dermatitis as well as the recovery from the dermatitis were
regulated by key loci where candidate genes regulate the MAPK/
ERK pathway. These findings have far-reaching implications in
the management of ACD and point toward new therapeutic
targets.
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resulting from pollen composition and
not from protein-intrinsic allergenicityTo the Editor:
Birch (Betula verrucosa) pollen is the main cause of spring
pollinosis in the temperate climate zone of the Northern
Hemisphere. Approximately 95% of birch pollen–allergic
patients are sensitized to Bet v 1, the major birch pollen allergen.1
However, it is not known whether sensitization toward Bet v 1
results from its own intrinsic properties or from immunomodula-
tory pollen compounds codelivered with the allergen. Therefore,
we investigatedwhether Bet v 1 or the pollenmatrix is responsible
for the activation of antigen-presenting cells and the subsequent
TH2 polarization, relevant in the process of allergic sensitization.
Because dendritic cells (DCs) are the most potent activators of
adaptive immune responses, we sought to investigate their role in
the process of allergic sensitization toward Bet v 1. For this
purpose, the activation of murine bone marrow–derived dendritic
cells (mBMDCs) as well as the maturation of human monocyte–
derived dendritic cells was monitored in vitro. Concerning the
latter, PBMCs were isolated either from healthy, nonatopic
donors or from atopic patients. Cells were stimulated either
with recombinant Bet v 1.0101 (rBet v 1) produced in E coli or
with an aqueous birch pollen extract (BPE).We analyzed whether
DC activation is triggered by the costimulation of Toll-like
receptor (TLR) 4 by LPS contaminations found in BPE, termed
nLPS. Furthermore, we investigated the capacity of rBet v 1
and BPE to induce TH2 polarization using an in vivo sensitization
model. The methodology can be found in this article’s Online
Repository at www.jacionline.org.
The upregulation of maturation markers (CD40 and CD86)
expressed on CD11c1 mBMDCs was monitored over 24 hours
(Fig 1, A). The nLPS concentration was determined by using a
CD11c+ CD86+
CD11c+ CD40+
BPE rBet v 1 rBet v 1+nLPS nLPS LPS 100ng/ml
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FIG 1. A, Time-dependent activation ofmurine BMDCs stimulatedwith BPE or rBet v 16 nLPS. B, Comparison
of activation signal induced by rBet v 1 or nBet v 1. Expression of maturation markers (C) and cytokine profile
of human moDCs stimulated with BPE. a.u., Arbitrary units of fluorescence;MFI, mean fluorescence intensity;
Unstim, unstimulated. Error bars indicate mean and SEM (*P <_ .05; **P <_ .01; ***P <_ .001).
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article’s Online Repository at www.jacionline.org). Here,
0.4 ng/mL of LPS had an equivalent capacity of 1 mg/mL of total
soluble BPE protein to activate TLR4 and TLR2. As positive
control, cells were incubated with LPS at a concentration of
100 ng/mL, 250-fold higher than nLPS. Compared with the basal
activation of uninduced cells (Fig 1, A, dashed line), BPE induced
a time-dependent upregulation of CD86 and CD40. Stimulation
with rBet v 1, even in the presence of nLPS, was not sufficient to
mimic this effect. Because rBet v 1 represents just one of many
isoforms found in BPEs, we investigated whether the activation
of mBMDCs differs on stimulation with a natural Bet v 1 isoform
mixture (nBet v 1) purified from BPE (Fig 1, B). No differences
were observed between both natural and recombinant Bet v 1.Furthermore, we analyzed the maturation (CD40, HLA-DR,
CD80, CD83, and CD86) and secretion of the cytokines CCL17,
IL-1b, IL-10, IL-6, IL-12p70, and IL-23 of human moDCs on
stimulation with the major allergen. In parallel, the maturation-
inducing effects of BPE were determined and compared with
nLPS alone. The concentration of nBet v 1 in BPE was
determined by ELISA and rBet v 1 was used in equivalent
amounts. No maturation was induced by rBet v 1 (see Fig E2, A
and B, in this article’s Online Repository at www.jacionline.
org). In contrast, BPE induced an upregulation of maturation
markers and IL-6 secretion in comparison to the unstimulated
and/or nLPS-stimulated control (Fig 1, C). Surprisingly, in
moDCs derived from nonatopic donors, the maturation effect
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FIG 2. A, Flow cytometry gating strategy used to quantify CD41 IL-4 GFP1 T cells. B, Percentage of IL-4–
expressing CD41 T cells of mice immunized with rBet v 1 or BPE. C, Comparison of nBet v 1–depleted and
rBet v 1–replaced extracts with untreated BPE; *P <_ .05; **P <_ .01; ***P <_ .001. D, Schematic overview of nBet
v 1 depletion of BPE using immunoprecipitation. E, mRNA expression of in vitro–stimulated human naive
CD41 T cells with BPE. FSC-A, Forward scatter-area; SSC-A, side scatter-area.
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LETTERS TO THE EDITOR 987was observable. Without LPS costimulation secretion of neither
IL-12p70 nor IL-23 by BPE-stimulated moDCs was observable
(data not shown).
The finding that BPE but not rBet v 1 is able to effectively
activate DCs raised the question whether pollen-derived
compounds possess adjuvant properties and thus contribute to
the allergenicity of Bet v 1 in vivo. Therefore, we examined the
capacity of BPEs and rBet v 1 to promote TH2 polarization. We
used IL-4/GFP-enhanced transcript (4get) mice for monitoring
the expression of the TH2 cytokine IL-4 in skin-draining
inguinal lymphocytes (Fig 2, A). Strikingly, rBet v 1 did not
cause TH2 polarization; however, BPE strongly induced IL-4
activation (Fig 2, B). Because the involvement of the allergen
itself as part of BPE in TH2 polarization was unclear,
we addressed this question by immunizing 4get mice with a
Bet v 1–depleted BPE (nBet v 1–depleted extract; Fig 2, D;
see Fig E3, A-D, in this article’s Online Repository at
www.jacionline.org) and a rBet v 1–reconstituted version
(rBet v 1–replaced extract). Indeed, the TH2-promoting effect
of the BPE remained even after the depletion (Fig 2, C),
indicating that TH2 polarization is induced via an
allergen-independent costimulus. In addition, the in vitro
activation of mBMDCs from 4get mice was analyzed (see Fig
E4 in this article’s Online Repository at www.jacionline.org).
To analyze potential direct effects of BPE on naive CD41
T cells, we activated T cells by treatment with aCD3/aCD28
and BPE. Although the expression of aCD3/aCD28-stimulated
TH2-specific cytokines IL-5 and IL-13 was enhanced on addi-
tional stimulation with BPE (0.1%), BPE treatment did not affect
the expression of the TH1-related cytokines IL-2 and TNF-a.
Summarizing, we found that BPE efficiently activates murine
and human DCs in vitro and is able to induce TH2 polarization
in vivo and in vitro, whereas Bet v 1 lacks this property. These
observations strongly support a role for the pollen context.
Noteworthy, TH2 polarization upon immunization with BPE
occurred independently of Bet v 1, indicating that the protein
itself is not the sensitization-driving force.
Equivalent amounts of LPS (nLPS) in BPE are not capable of
inducingDCmaturation comparedwith thewhole BPE, suggesting
that the observed activation cannot be attributed to LPS contam-
inations. However, LPS may not be the effective TLR-activating
factor present in BPE because other contaminants are also present
in pollen extracts. Previous studies demonstrating that pollen
extracts promote maturation of TLR4-deficient DCs and that
recognition of allergens is largely independent of TLR correlates
with our observation.2-4 Hence, allergenicity may be explained by
recognition of functional features of antigens.5-7 BPE-stimulated
moDCs derived from nonatopic donors showed a significant
reduction in maturation that may arise because of an increase in
the anti-inflammatory cytokine, IL-10, which has been previously
associated with downregulation of maturation activity.8
Remarkably, Bet v 1–depleted BPEwas still able to induce TH2
polarization. Therefore, we propose that Bet v 1 sensitization
occurs as a result of additional immune interactions elicited by
pollen-derived components that are not necessarily associated
with the major allergen itself. Whether allergic sensitization
toward Bet v 1 arises as a secondary effect of a preprimed TH2
environment3 and/or due to the high levels of Bet v 1 in BPEs
remains to be determined in future studies.9 In this respect,
the identification of TH2-polarizing compounds in pollen
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METHODS
Recombinant protein expression, purification, and
characterization of Bet v 1
The expression and purification of rBet v 1 was performed as previously
described.E1 In brief, rBet v 1 was expressed in Escherichia coli BL21 Star
(DE3) cells (Invitrogen, Carlsbad, Calif) and purified by protein precipitation
with 200 mM sodium chloride, followed by low-pressure chromatography us-
ing 10 mL of Phenyl Sepharose and a DEAE Sepharose column (GE Health-
care Biosciences, Little Chalfont, UK). The levels of endotoxin contamination
were determined by EndoZyme recombinant Factor C assay (Hyglos GmbH,
Bernried am Starnberger See, Germany). The endotoxin amounts did not
exceed 0.3 ng/mL. The recombinant protein was physicochemically charac-
terized and stored lyophilized at 2208C.
Aqueous BPE
A total of 5 mg of Betula pendula (Allergon AB, €Angelholm, Sweden) pol-
len was dissolved in PBS and shaken for 24 hours at 48C. The suspension was
centrifuged 3 times for 5 minutes each at 12,000g at 48C. The supernatant was
collected and filtered through a 0.2-mm pore-size sterile filter (Merck Milli-
pore, Merck KGaA, Darmstadt, Germany).
Purification of natural Bet v 1
For the purification of natural Bet v 1 (nBet v 1), an extract of 5 mg of Be-
tula pendula (Allergon AB, €Angelholm, Sweden) pollen, prepared in a buffer
consisting of 50 mL of endotoxin-free H20 and 0.5 mol NaCl, was shaken for
5 minutes at room temperature at 1400 rpm and then centrifuged for 5 minutes
at 12,000g at 48C; the resulting supernatant was filtered (0.45-mm filter, GE
Healthcare Biosciences). Natural Bet v 1 was purified by a combination of hy-
drophobic chromatography on a 10-mL Phenyl Sepharose column and size-
exclusion chromatography using a Superdex 75 10/300 GL column (both
from GE Healthcare Biosciences). The purified protein was physicochemi-
cally characterized and stored at2208C. The nBet v 1 preparation represented
a heterogeneous mixture of the following isoforms, as determined by mass
spectrometry: Bet v 1a (MS score, 492.42; coverage, 93.13), Bet v 1f (MS
score, 507.42; coverage, 73.75), Bet v 1g (MS score, 401.48; coverage,
70.63), Bet v 1m (MS score, 454.27; coverage, 67.50), and several other Bet
v 1–derived fragments.
Determination of LPS level in BPE
To assess the amount of nLPS in BPEs, TLR4- and TLR2-specific nuclear
factor kappa B (NF-kB) reporter gene assays were performed (as described
elsewhereE2). A total of 400 ng of NF-kB-luciferase reporter plasmid (kindly
provided by Min Li-Weber and cloned into pGL3Neo in the laboratory of J.
Horejs-Hoeck) was transfected into HEK293 cells alongside a TLR4 receptor
mix (with a TLR4:MD2:CD14 ratio of 3:1:1) or a TLR2 receptor mix (with a
TLR2:CD14 ratio of 1:1) using Lipofectamine 2000 (Invitrogen, Thermo
Fisher Scientific, Waltham, Mass) according to the manufacturer’s protocol.
TLR4, TLR2, CD14, and MD-2 were kind gifts from Andrei Medvedev and
Douglas Golenbock. To estimate the LPS concentration, NF-kB activation
in response to BPE was compared with the NF-kB activation induced by an
LPS standard (starting from 10 pg/mL to 100 ng/mL). LPS from E coli
O111:B4 was purchased from Sigma-Aldrich, Inc (St Louis, Mo). For the
data analysis, a representative value present on both logarithmic trend lines
(Fig E1, C) in the parallel area (red line) was chosen for the calculation of
the amount of LPS in BPE. Based on the LPS standard curve, the amount of
LPS in BPE was determined as 0.4 ng/mL LPS per 1 mg/mL BPE. For the
calculation of the amount of LPS, the TLR4/CD14/MD2 data were used.
The assay was performed and quantified in triplicates.
In vitro maturation of mBMDCs
The isolation of BMDCs from C57BL/6 mouse bone marrow was
performed as described previously.E3 In brief, bone marrow cells were
extracted from femalemouse femora and cultured in RPMI 1640medium sup-
plemented with 5% FCS, 2 mM L-glutamine, 1% penicillin-streptomycin,
20% GM-CSF supernatant, and 200 mM b-mercaptoethanol (mBMDC me-
dium). After 10 days of culture, the cells were either frozen or used fresh
for in vitro DC stimulation experiments. BMDCs were treated over a certain
period of time (24, 14, 6, 3, 1, or 0 hours) with 0.5 mg of rBet v 1 or nBet v
1 per 2 3 105 cells. As a reference, nLPS without the protein was dissolved
in mBMDC medium and incubated similarly. The nLPS samples contained
400 pg/mL of LPS per 1 mg/mL rBet v 1. Cells were stained with
allophycocyanin (APC)-conjugated antimouse CD11c antibody (clone
N418; eBioscience, Inc, San Diego, Calif), fluorescein isothiocyanate
(FITC)-conjugated anti-mouse CD86 antibody (clone GL-1; BioLegend,
San Diego, Calif), PerCP/Cy5.5 anti-mouse CD40 antibody (clone 3/23;
BioLegend), or BV421 anti-mouse CD80 antibody (16-10A1; BioLegend)
and analyzed via flow cytometry. Measurements were performed on a
FACSCanto II instrument (BD Biosciences, San Jose, Calif). Dead cells
were excluded on staining with the fixable viability stain 450 (BD
Biosciences), and granulocytes and monocytes with the V450 Rat
anti-Mouse LY-6G and LY-6C (BD Biosciences). For compensation and
data analysis, BD FACSDiva software (BD Biosciences) was used.
Unstimulated cells were treated only with BMDC medium. As a positive
control, 100 ng/mL LPS was used. The aqueous BPE was used at the same
concentration of total protein as rBet v 1 (0.5 mg/2 3 105 cells). Statistical
analysis was performed using ANOVA with a Bonferroni posttest. The data
represent the mean of duplicate experiments. *P < .05, **P < .01, and
***P < .001 indicate significantly different values versus the unstimulated
cells. The data are derived from at least 2 independent experiments.
Stimulation of human moDCs and analysis of
cytokine profile
MoDCs were isolated from PBMCs of healthy, nonatopic donors as well as
of atopic patients and cultured as previously described.E4 Immature moDCs
(1 3 106 cells/mL) were checked for viability with Aqua dye (Invitrogen,
Carlsbad, Calif), expression of CD1a (eBioscience, Inc), and loss of CD14
(BD Biosciences) expression by flow cytometry. Cells were stimulated for
24 hours with 1000 ng/mL of rBet v 1. As a control, moDCs were treated
with medium (unstimulated control). In another experiment, the stimulation
effect of 30mg/mL of BPE onmoDCs was compared with the naturally occur-
ring amount of LPS (nLPS) in the extract. By using a Bet v 1–specific sand-
wich ELISA (see section: Bet v 1 depletion by immunoprecipitation), the
concentration of BPE was calculated to obtain amounts of nBet v 1 equivalent
to 1000 ng/mL of rBet v 1. The assay was performed without LPS costimula-
tion. The maturation markers CD40 (eBioscience), HLA-DR, CD80, CD83,
and CD86 (BD Biosciences) were analyzed by FACS analysis on a Navios
flow cytometer (Beckman Coulter, Brea, Calif). The supernatant of the stim-
ulated cells was collected and analyzed for cytokine expression, including
CCL17, IL-1b, IL-10 (BD Biosciences), IL-6, IL-12p70, and IL-23 (eBio-
science). Statistical analysis was performed using 1-way ANOVAwith a Bon-
ferroni posttest to compare all groups. All statistical calculations were
performed using GraphPad Prism 5 software. The study was approved by
the ethics committee of the medical faculty of Technical University of
Munich.
In vitro stimulation of human naive CD41 T cells
and analysis of mRNA expression
Naive CD41 T cells were isolated from PBMCs of healthy and anonymous
blood donors bymagnetic cell separation according to manufacturer’s instruc-
tions (Naive CD41 T-cell Isolation Kit II, Miltenyi Biotec, Bergisch Glad-
bach, Germany). The blood samples were provided by the university
hospital for blood group serology and transfusion medicine in Salzburg. T
cells were seeded in 48-well plates at a density of 2 3 106 cells per milliliter
in Iscove’s Modified Dulbecco’s Medium (PAA Laboratories GmbH, Pasch-
ing, Austria) supplemented with 5% FCS i.a. (PAA), 2 mM L-glutamine,
100 U/mL penicillin (Sigma-Aldrich, Inc, St Louis, Mo), and 100 mg/mL
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streptomycin (Sigma) and stimulated with 0.1 mg/mL aCD3 (Anti-Human
CD3 Functional Grade Purified, Clone: OKT3, eBioscience), 2.5 mg/mL
aCD28 (Purified NA/LE Mouse Anti-Human CD28, BD Biosciences, San
Jose, Calif), and 0.01% and 0.1% of BPE. After 7 days, cells were restimulated
for another 6 hours and T-cell cytokine mRNA expression was measured by
quantitative PCR. Total RNA was isolated by using TRI Reagent (Sigma)
and reverse-transcribed into cDNA with RevertAid H Minus Reverse Tran-
scriptase (Thermo Fisher Scientific). mRNA expression was analyzed rela-
tively to the large ribosomal protein P0 (RPLP0) by quantitative real-time
PCR (Rotor-Gene Q, Rotor-Gene Q Series Software, Quiagen, Hilden, Ger-
many) with iQ SYBR Green Supermix (Bio-Rad, Hercules, Calif) and the
following primers: RPLP0: forward 59-GGCACCATTGAAATCCTGAG
TGATGTG-39, reverse 59-TTGCGGACACCCTCCAGGAAG-39, IL-5:
forward 59-CCTTGGCACTGCTTTCTACTCATCG-39, reverse 59-GGT
TTACTCTCCGTCTTTCTTCTCCACA-39, IL-13: forward 59-TGTG
CCTCCCTCTACAGCCCTCAG-39, reverse 59-TCAGCATCCTCTGGGT
CTTCTCG-39, IL-2: forward 59-TCCCAAACTCACCAGGATGCTCAC-39,
reverse 59-AATGTTGTTTCAGATCCCTTTAGTTCCAGA-39, TNF-a:
forward 59-CAAGCCTGTAGCCCATGTTG-39, reverse 59-GAGGTTGA
CCTTGGTCTGGTA-39. Statistical significance was determined by 1-way
ANOVA, Tukey posttest (*P < .05, **P < .01, ***P < .001).
According to the Austrian national regulations, informed consent in the
case of anonymous blood cells discarded after plasmapheresis (buffy coats) is
not required. Thus, there is no requirement for additional approval by the local
ethics committee.
Bet v 1 depletion by immunoprecipitation
Depletion was performed by immunoprecipitation using mouse mono-
clonal anti–Bet v 1.0101 antibodies, which were generated by hybridoma
technology and purified using Bet v 1.0101–coupled NHS Sepharose 4 Fast
Flow (GE Healthcare Biosciences) material. A total of 1 mL of Protein G
Sepharose 4 Fast Flow (also GE Healthcare Biosciences) was preincubated
with PBS containing 0.1%BSA to saturate the nonspecific binding sites of the
Protein G Sepharose material. A total of 0.5 mL of BPE (1 mg/mL) was
incubated with 250mg of the anti–Bet v 1.0101 antibody and shaken overnight
at 48C. The suspension was incubated with 1 mL of the Protein G Sepharose
slurry over 30 to 60 minutes at room temperature. The suspension was
centrifuged for 15 minutes at 14,000g, and the supernatant containing the Bet
v 1–depleted extract was collected. The concentration of the depleted extract
was determined by Bradford assay. The depleted extract was analyzed by so-
dium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblotting. For the immunoblot assay, the same monoclonal anti–Bet
v 1.0101 antibody was used as a primary antibody. As a secondary antibody,
an alkaline phosphatase-conjugated rabbit anti-mouse IgG 1 IgM antibody
(Jackson ImmunoResearch Europe Ltd, Oaks Drive Newmarket, Suffolk,
UK) was used at a concentration of 1 mg/mL. The amount of Bet v 1 within
the depleted extract was determined by sandwich ELISA using the mouse
monoclonal anti–Bet v 1.0101 antibody in combination with an affinity-
purified polyclonal rabbit anti–Bet v 1.0101 antibody (1 mg/mL). The detec-
tion antibody was an alkaline phosphatase-conjugated goat anti-rabbit
antibody (1 mg/mL). The depleted extract was compared with the untreated
extract and an rBet v 1 standard. For the rBet v 1–replaced extract sample,
the exact amount of rBet v 1 was added to restore the level to 12.5%, which
was the level of Bet v 1 in the original, untreated extract. Furthermore, the
depleted extract was analyzed using mass spectrometry with a Q-Exactive Or-
bitrap Mass Spectrometer (Thermo Fisher Scientific, Waltham, Mass) with
nanoelectrospray and nano-HPLC (Dionex Ultimate 3000, Thermo Fisher
Scientific).
Immunization of 4get mice
4get mice (Jackson laboratory, Bar Harbor, Me) were immunized with
either BPE (n5 5) or rBet v 1 (n5 3) in PBS, without added adjuvants. For the
immunizations, 65 mg of BPE was injected, and the amount of injectable rBet
v 1 was calculated according to the total Bet v 1 quantified within the BPE.
Skin-draining inguinal lymph nodes of immunized mice, as well as of naive
mice, were collected. Lymphocytes were stained with an APC-conjugated
anti-mouse CD4 antibody and analyzed for IL-4/eGFP expression using flow
cytometry (BDBiosciences). In a second experiment, a different batch of BPE
(n5 5) was used and compared with a Bet v 1–depleted version of this extract
(nBet v 1–depleted extract, n 5 5) as well as a reconstituted version of the
depleted extract (rBet v 1–replaced extract, n5 5). The results were compared
with those of naive 4get mice. Statistical analysis was performed using 1-way
ANOVAwith a Bonferroni posttest to compare all groups (*P <_.05; **P <_.01;
***P <_ .001). All in vivo experiments were performed according to national
guidelines approved by the Austrian Federal Ministry (BMWF-66.012/
0010-II/3b/2013).
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FIG E1. TLR2- (A) and TLR4-specific (B) NF-kB activation was induced either by a BPE or by LPS. Either the
TLR2 or the TLR4 receptor complex was overexpressed in HEK293 cells. Cells were stimulated either with
different concentrations of LPS or the BPE, starting from 10 pg/mL to 100 ng/mL. By comparing the activa-
tion signals obtained by LPS, the level of LPS in the BPE was quantified by using linear regression. For the
calculation of the amount of LPS, the standard curve of the TLR4/CD14/MD2 data was used (C). The assay
was performed and quantified in triplicates. NF-kB, Nuclear factor kappa B; unstim, unstimulated.
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FIG E2. Activation (A) and cytokine expression (B) of humanmoDCs induced by rBet v 1.Unstim., Unstimu-
lated. Error bars indicate mean and SEM (*P <_ .05; **P <_ .01; ***P <_ .001).
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12.5 % nBet v 1



























































nBet v 1-depleted extract
FIG E3. Depletion of nBet v 1 from BPE and replacement with rBet v 1. The BPE was depleted of Bet v 1 by
immunoprecipitation using allergen-specific mAbs. With this procedure, it was possible to reduce the
amount of nBet v 1 measured within the extract from 12.5% to 2%. SDS-PAGE analysis of the samples used
in the 4get experiment (Fig 2, B): rBet v 1, birch pollen extract, nBet v 1–depleted extract, and rBet v
1–replaced extract (A). Immunoblot of SDS-PAGE samples using amonoclonal mouse anti–Bet v 1 antibody
as the primary antibody (B). The reduction of nBet v 1 within the nBet v 1–depleted extract was quantified by
sandwich ELISA (C). The rBet v 1–replaced extract was reconstituted equivalently to the 12.5% of nBet v 1
found in the original extract. The question whether or not all nBet v 1 isoforms were reduced by immuno-
precipitation was addressed bymass spectrometry (D). For this purpose, the control proteins Bet v 2 and Bet
v 7were used to normalize themass spectrometry data. All the isoforms found in the BPE (Bet v 1.0101, Bet v
1.0102, Bet v 1.0104, Bet v 1.0106, and Bet v 1.0201) were markedly reduced after the immunoprecipitation.
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FIG E4. Activation of CD11c1 mBMDCs isolated from 4get mice on stimulation with BPE, nBet v 1–depleted
BPE (dBPE), or rBet v 1 6 nLPS for 24 hours. The expression of the surface activation markers CD80 and
CD40 was analyzed.
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